Human Genome Sciences (HGSI) 9.52 -0.49

Human Genome Sciences, Inc.
(HGSI) 9.52 -0.49

Last Trade:	9.51	Day Range:	9.42 - 9.84
Trade Time:	08:02PM	52wk Range:	6.51 - 30.15
Prev. Close:	10.00	Market Cap:	1.89B
Open:	9.84	Div Yield:	0
Volume:	7480103	PE:	-50
EPS:	-2.02

The Latest On HGSI

Benzinga's M&A Chatter for Thursday February 9, 2012 2/9/12 5:58pm

Fast Money Picks For February 7th 2/6/12 7:22pm

Benzinga's M&A Chatter for Wednesday January 25, 2012 1/25/12 8:04pm

Benzinga's M&A Chatter for Friday January 6, 2012 1/6/12 4:51pm

Goldman Sachs Maintains Neutral on Human Genome Sciences Despite Weakened Benlysta Sales 12/29/11 9:18am

Citigroup Lowers PT on Human Genome Sciences to $8 12/21/11 10:05am

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11 5:47pm

Brean Murray Carret Reiterates Hold Rating on Human Genome Sciences 11/16/11 2:15pm

Human Genome Sciences Completes Offering of $494.5M of Convertible Senior Notes 11/7/11 12:21pm

Human Genome Sciences Announces Multiple Abstracts Related to BENLYSTA and Systemic Lupus Erythematosus to Be Presented at the 2011 ACR/ARHP Meeting 11/4/11 6:04am

Human Genome Sciences Announces Exercise of Option to Purchase Additional Notes for Total Convertible Notes Issuance of $494.5 Million 11/3/11 6:02am

Human Genome Sciences Prices $430 Million Convertible Notes Issuance 11/2/11 10:43am

Benzinga's M&A Chatter for Thursday February 9, 2012 2/9/12

Fast Money Picks For February 7th 2/6/12

Benzinga's M&A Chatter for Wednesday January 25, 2012 1/25/12

Benzinga's M&A Chatter for Friday January 6, 2012 1/6/12

Goldman Sachs Maintains Neutral on Human Genome Sciences Despite Weakened Benlysta Sales 12/29/11

Citigroup Lowers PT on Human Genome Sciences to $8 12/21/11

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11

Brean Murray Carret Reiterates Hold Rating on Human Genome Sciences 11/16/11

Human Genome Sciences Completes Offering of $494.5M of Convertible Senior Notes 11/7/11

Human Genome Sciences Announces Multiple Abstracts Related to BENLYSTA and Systemic Lupus Erythematosus to Be Presented at the 2011 ACR/ARHP Meeting 11/4/11

Human Genome Sciences Announces Exercise of Option to Purchase Additional Notes for Total Convertible Notes Issuance of $494.5 Million 11/3/11

Human Genome Sciences Prices $430 Million Convertible Notes Issuance 11/2/11

Benzinga's M&A Chatter for Thursday February 9, 2012 2/9/12

Fast Money Picks For February 7th 2/6/12

Benzinga's M&A Chatter for Wednesday January 25, 2012 1/25/12

Benzinga's M&A Chatter for Friday January 6, 2012 1/6/12

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11

Fast Money Picks For November 2nd (XRT, HGSI, AKS, CFN) 11/1/11

Trending Investor Searches: Top Four Searched Stocks 10/26/11

Mad Money Lightning Round: Cramer Likes Juniper Networks, Apple 10/14/11

Stocks to Watch for Wednesday 8/03/2011: Fresh 52 Week Highs and Lows 8/3/11

Stocks to Watch for Tuesday 8/02/2011: Fresh 52-Week Highs and Lows 8/2/11

Stocks to Watch for Thursday 7/28/2011: Fresh 52 Week Highs and Lows 7/28/11

Stocks to Watch for Tuesday 7/26/2011: Fresh 52 Week Highs and Lows 7/26/11

Goldman Sachs Maintains Neutral on Human Genome Sciences Despite Weakened Benlysta Sales 12/29/11

Citigroup Lowers PT on Human Genome Sciences to $8 12/21/11

Brean Murray Carret Reiterates Hold Rating on Human Genome Sciences 11/16/11

End-of-Day Market Summary for October 26, 2011 10/26/11

Brean Murray Downgrades Human Genome Sciences to Hold, Removes PT 10/26/11

UPDATE: Piper Jaffray Lowers PT to $15 on Human Genome Sciences 10/26/11

Piper Jaffray Lowers PT on Human Genome Sciences to $15 10/26/11

Piper Jaffray Believes Timing is Right for GSK to Buy Human Genome Sciences 10/18/11

UPDATE: Bank of America Merrill Lynch Lowers PO on Human Genome Sciences to $13 9/2/11

Bank of America Lowers PO On Human Genome Sciences To $13 9/2/11

UPDATE: Citi Lowers Price Target On Human Genome Sciences To $15 8/31/11

Citigroup Lowers PT On Human Genome Sciences To $15 8/31/11

Trade HGSI
NOW!

Partner Headlines

GlaxoSmithKline Swings To Profit But Shy Of Estimates 2/7/12

6 Drug Stocks Unworthy of Biotech Bull Market 2/7/12

Gilead, Celgene Join Big Pharma On M&A Front 1/27/12

Benlysta Sales Expected to Improve - Analyst Blog 1/10/12

5 Stocks Under $10 Set to Trigger Big Moves 1/9/12

Dendreon: Provenge Q4 Sales Beat 1/5/12

Glaxo/HGSI Initiate New Study - Analyst Blog 12/19/11

Human Genome Upped to Neutral - Analyst Blog 12/9/11

Press Releases

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BIO CEO and Investor Conference 2/10/12 Business Wire Story

Critical Alerts For Halliburton, Travelers, Express Scripts, HCA, and Human Genome Sciences Released By Seven Summits Research 2/7/12 Newswire Story

Zeldes & Haeggquist, LLP Announces Investigation of Human Genome Sciences, Inc. (HGSI) 2/6/12 Business Wire Story

Human Genome Sciences Reports Progress with Commercialization of BENLYSTA® and Announces 2012 Goals at JPMorgan Healthcare Conference 1/9/12 Business Wire Story

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference 1/5/12 Business Wire Story

Robbins Umeda LLP Announces an Investigation of Human Genome Sciences, Inc. 12/29/11 Business Wire Story

Pomerantz Reminds Shareholders of Human Genome Sciences, Inc. of Upcoming Deadline - HGSI 12/16/11 GlobeNewswire Story

Human Genome Sciences and GlaxoSmithKline Initiate Phase 3 Trial of Belimumab (BENLYSTA®) Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus 12/15/11 Business Wire Story

Quarterly Changes to the NASDAQ Q-50 Index 12/9/11 GlobeNewswire Story

Critical Alerts for JPMorgan Chase, Sina, Aetna, Human Genome Sciences, and SunTrust Released by Seven Summits Research 12/7/11 Newswire Story

Pomerantz Reminds Shareholders of Human Genome Sciences, Inc. of Upcoming Deadline -- HGSI 12/2/11 GlobeNewswire Story

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference 12/1/11 Business Wire Story

Get the latest HGSI stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Human Genome Sciences, Inc. stock price.

Human Genome Sciences, Inc. by YCharts